MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment.
Lazure P. et al, (2022), Liver Int
Is autonomous cortisol secretion sexually dimorphic?
Pofi R. and Tomlinson JW., (2022), Lancet Diabetes Endocrinol
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.
McPherson S. et al, (2022), Lancet Gastroenterol Hepatol
AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.
Gathercole LL. et al, (2022), J Endocrinol, 253, 97 - 113
Is it time for chronopharmacology in NASH?
Marjot T. et al, (2022), J Hepatol